1. Stryker intends to acquire the remaining shares of the French company soon.
2. Stryker plans to file a proposed public buyout offer and a squeeze-out for the additional shares. Both must be cleared by the French stock market authority.
3. The remaining shares will cost Stryker about $24.88 each through the buyout offer.
4. Stryker expects the squeeze-out to occur during the second quarter of 2018.
5. The manufacturer of the SpineJack implant, Vexim develops minimally invasive solutions for traumatic spinal pathology treatment.
6. Announced in October 2017, Stryker’s deal to acquire Vexim was worth $216 million.
More articles on supply chain:
Orthofix to conduct rotator cuff repair study — 5 highlights
5 cost-saving supply chain management strategies from Regent Surgical Health
Healthcare organizations adapting to decreased IV fluid supply — 5 insights
